Sudarshan Pharma Industries Ltd: Technical Momentum Shifts Amid Mixed Indicator Signals

Technical Trend and Price Movement

The stock closed at ₹37.24 on 5 Oct 2026, marginally down by 0.16% from the previous close of ₹37.30. The day’s trading range was relatively narrow, with a low of ₹36.20 and a high matching the close at ₹37.24. Over the past 52 weeks, Sudarshan Pharma’s price has fluctuated between ₹18.50 and ₹42.79, reflecting significant volatility typical of micro-cap stocks in the Specialty Chemicals industry.

The recent technical trend has shifted from a sideways pattern to a mildly bullish one, signalling a tentative improvement in price momentum. This shift is supported by daily moving averages, which currently indicate a mildly bullish stance, suggesting that short-term price averages are beginning to trend upwards. However, the weekly and monthly moving averages have not shown a strong bullish confirmation, indicating that the trend remains fragile.

MACD and Momentum Oscillators

The Moving Average Convergence Divergence (MACD) indicator, a key momentum oscillator, remains mildly bearish on both weekly and monthly timeframes. This suggests that despite the recent uptick in price momentum, the underlying momentum is not yet robust enough to confirm a sustained upward trend. The MACD’s mild bearishness implies that the stock could face resistance in breaking out decisively in the near term.

Relative Strength Index (RSI) readings on weekly and monthly charts currently show no clear signal, hovering in neutral zones. This lack of directional RSI momentum indicates that the stock is neither overbought nor oversold, which aligns with the observed sideways to mildly bullish price action. Investors should watch for any RSI movement beyond the typical 30-70 range to identify stronger momentum shifts.

Bollinger Bands and Volatility

Bollinger Bands provide insight into price volatility and potential breakout points. On the weekly chart, the bands are signalling a bearish trend, suggesting that price volatility may be contracting with a downward bias. Conversely, the monthly Bollinger Bands indicate a mildly bullish stance, hinting at a longer-term potential for price expansion to the upside. This divergence between weekly and monthly signals underscores the mixed technical environment Sudarshan Pharma currently faces.

Other Technical Indicators: KST, Dow Theory, and OBV

The Know Sure Thing (KST) indicator is mildly bearish on the weekly timeframe but bullish on the monthly chart. This split suggests that while short-term momentum may be weakening, the longer-term trend could be improving. Similarly, Dow Theory assessments show a mildly bearish weekly outlook but a mildly bullish monthly perspective, reinforcing the notion of a nascent longer-term uptrend amid short-term caution.

On-Balance Volume (OBV) data is currently inconclusive, with no clear signals on weekly or monthly charts. This absence of volume confirmation means that price moves are not yet strongly supported by trading activity, which is a critical factor for validating trend strength.

Comparative Returns and Market Context

Examining Sudarshan Pharma’s returns relative to the Sensex provides valuable context for its performance. Over the past week, the stock declined by 2.46%, slightly underperforming the Sensex’s 2.27% drop. Over the last month, the stock’s fall of 3.55% was less severe than the Sensex’s 6.54% decline, indicating some relative resilience.

Year-to-date (YTD), Sudarshan Pharma has delivered a remarkable 35.17% return, vastly outperforming the Sensex’s negative 15.62% return. Over the last year, the stock’s gain of 46.15% contrasts sharply with the Sensex’s 11.20% loss, highlighting strong long-term momentum despite recent short-term volatility.

Looking further back, the stock’s three-year return stands at an impressive 342.81%, dwarfing the Sensex’s modest 9.24% gain over the same period. This exceptional performance underscores the company’s growth trajectory within the Specialty Chemicals sector, although the absence of five- and ten-year data limits longer-term trend analysis.

Mojo Score and Rating Update

MarketsMOJO’s latest assessment assigns Sudarshan Pharma a Mojo Score of 48.0, reflecting a cautious stance. The company’s Mojo Grade was downgraded from Hold to Sell on 28 Sep 2026, signalling a deterioration in technical and fundamental outlooks. This downgrade aligns with the mixed technical signals and the micro-cap status of the stock, which often entails higher volatility and risk.

Investors should weigh this downgrade carefully against the stock’s strong historical returns and recent mild bullish technical trend. The micro-cap classification also suggests limited liquidity, which can exacerbate price swings and complicate entry or exit decisions.

Investment Implications and Outlook

For investors considering Sudarshan Pharma, the current technical landscape suggests a cautious approach. The mildly bullish daily moving averages and monthly Bollinger Bands offer some optimism for a potential upward move. However, the weekly MACD and KST indicators’ bearish leanings, combined with neutral RSI readings and inconclusive volume support, counsel prudence.

Given the stock’s strong long-term returns and recent technical trend shift, it may be appropriate for risk-tolerant investors to monitor for confirmation of a sustained bullish breakout. Key levels to watch include the recent 52-week high of ₹42.79, which would signal renewed strength, and the 52-week low of ₹18.50, which remains a distant but important support level.

Investors should also consider the broader market environment and sector-specific factors affecting Specialty Chemicals, as these will influence Sudarshan Pharma’s price trajectory. The micro-cap nature of the stock necessitates careful position sizing and attention to liquidity conditions.

Summary

Sudarshan Pharma Industries Ltd is at a technical crossroads, with a shift from sideways to mildly bullish momentum tempered by mixed signals from key indicators. While the stock’s long-term returns have been impressive, recent technical downgrades and cautious momentum oscillators suggest that investors should remain vigilant. The company’s Mojo Grade downgrade to Sell reflects these concerns, underscoring the need for careful analysis before committing capital.

Monitoring the evolution of MACD, RSI, moving averages, and volume indicators will be crucial in determining whether Sudarshan Pharma can sustain an upward trajectory or if it will face renewed selling pressure in the near term.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →